676136-31-5 Usage
Uses
Used in Pharmaceutical Synthesis:
(S)-5-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and reactivity make it a valuable component in the development of new drugs and medicines.
Used in Drug Discovery and Development:
In the pharmaceutical industry, (S)-5-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE is used as a key component in the preparation of chemical libraries for high-throughput screening. This process helps identify potential drug candidates by testing their interactions with various biological targets.
Used in Organic Chemistry Reactions:
(S)-5-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE serves as a reagent in organic chemistry, particularly in reactions involving the formation of carbon-carbon or carbon-nitrogen bonds. Its unique structure and functional groups make it a useful tool for creating new chemical entities.
Used in Biological Research:
(S)-5-BROMO-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE has been studied for its potential biological activities and pharmacological properties. Researchers are interested in its interactions with biological systems, which could lead to the discovery of new therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 676136-31-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,6,1,3 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 676136-31:
(8*6)+(7*7)+(6*6)+(5*1)+(4*3)+(3*6)+(2*3)+(1*1)=175
175 % 10 = 5
So 676136-31-5 is a valid CAS Registry Number.
676136-31-5Relevant articles and documents
MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
-
Paragraph 0541; 0559, (2021/01/23)
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS
-
Page/Page column 38, (2008/12/04)
Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.
